Optiver Holding’s Aclaris Therapeutics ACRS Stock Holding History

Optiver Holding’s Portfolio ACRS Stock Details ACRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.78K	Buy	+336	New	+$1.5K	﹤0.01%	2344

Other funds holding ACRS

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return

Optiver Holding's ACRS Position: Q2 2026 in Review

Optiver Holding opened a new position in Aclaris Therapeutics (ACRS) in Q2 2026: 336 shares worth $1.78K. The stake represents ﹤0.01% of the portfolio and ranks #2344 among its holdings.

149 funds tracked by Wall St. Rank hold ACRS as of Q2 2026.

Optiver Holding held 336 shares of Aclaris Therapeutics worth $1.78K as of Q2 2026.
Aclaris Therapeutics was a new Optiver Holding position in Q2 2026.
Aclaris Therapeutics made up ﹤0.01% of Optiver Holding's portfolio in Q2 2026, its #2344 holding.
149 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2026.

Based on Optiver Holding's 13F filing for Q2 2026, filed 12 Aug 2026.